LawrenceE.FeldmanMD

Oncology • Chicago, IL

Head & Neck Cancer, Thoracic Cancer

Professor Division of Hematology/Oncology Department of Medicine

Join to view full profile

Dr. Feldman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Feldman's full profile

Already have an account?

Office
840 S. Wood St.
Room 820-E (M/C 713)
Chicago, IL 60612
Phone+1 312-996-1581

Fax+1 312-413-4131

Summary

Dr. Lawrence Feldman is an oncologist in Chicago, IL and is affiliated with University of Illinois Hospital & Health Sciences System. He received his medical degree from University of Michigan Medical School and has been in practice 33 years. He specializes in head & neck cancer, hematologic oncology, and thoracic cancer and is experienced in thoracic oncology.

Education & Training

University of Michigan Medical SchoolClass of 1984

Certifications & Licensure

IL State Medical License 1991 - 2026
IN State Medical License 1992 - 1997
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2010 Mar 31
Active, not recruiting
Phase 3
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Everolimus Versus Placebo in Head and Neck Cancer Start of enrollment: 2010 Apr 01
Terminated
Phase 2
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2019 Jul 25
Active, not recruiting
Phase 2
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) Start of enrollment: 2019 Jul 26
Active, not recruiting
Phase 3
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Start of enrollment: 2020 Aug 13
Recruiting
Phase 3
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker Start of enrollment: 2020 Jul 20
Active, not recruiting
Phase 2
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Start of enrollment: 2021 Jul 12
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Brief Report: Precision Language and Deletion of the "S" Word.
Ciara Lockstadt, Mary M Pasquinelli, Jill Feldman, Jamie L Studts, Jamie S Ostroff
JTO Clinical and Research Reports. 2025-01-01
Letter to the Editor in Response to "Adherence to Annual Lung Cancer Screening in a Centralized Academic Program".
Julie Wu, Theodore Thomas, Hannah F Tavalire, Frances Vecchio, Tassos C Kyriakides
Clinical Lung Cancer. 2024-12-01
Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017.
Muhammad Furqan, Jyoti Malhotra, Ardaman Shergill, Li Liu, Sarah L Mott
Translational Lung Cancer Research. 2024-11-30

Press Mentions

Checking Out Emerging Approaches in Lung Cancer Treatment in ChicagoDecember 4th, 2019
Program to Address Opioid Prescribing for Lung, Head and Neck Cancer PatientsDecember 2nd, 2019
OncLive® Presents State of the Science Summit™ on Lung CancerOctober 10th, 2019
Join now to see all